Price Alert

Enanta Pharmaceuticals In... (ENTA)

NASDAQ: ENTA · Real-Time Price · USD

7.90

0.15 (1.94%)

At close: Sep 26, 2025, 3:59 PM

Enanta Pharmaceuticals Statistics

Share Statistics

Enanta Pharmaceuticals has 21.38M shares outstanding. The number of shares has increased by 0.89% in one year.

Shares Outstanding	21.38M
Shares Change (YoY)	0.89%
Shares Change (QoQ)	0.21%
Owned by Institutions (%)	87.47%
Shares Floating	19.97M
Failed to Deliver (FTD) Shares	200
FTD / Avg. Volume	0.11%

Short Selling Information

The latest short interest is 2.85M, so 13.33% of the outstanding shares have been sold short.

Short Interest	2.85M
Short % of Shares Out	13.33%
Short % of Float	14.16%
Short Ratio (days to cover)	13.78

Valuation Ratios

The PE ratio is -1.89 and the forward PE ratio is -2.55. Enanta Pharmaceuticals's PEG ratio is 0.13.

PE Ratio	-1.89
Forward PE	-2.55
PS Ratio	3.24
Forward PS	2.6
PB Ratio	1.7
P/FCF Ratio	-2.27
PEG Ratio	0.13

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Enanta Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.21, with a Debt / Equity ratio of 1.75.

Current Ratio	5.21
Quick Ratio	5.21
Debt / Equity	1.75
Debt / EBITDA	-2.16
Debt / FCF	-2.34
Interest Coverage	-11.12

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$516.3K
Profits Per Employee	$-885.84K
Employee Count	131
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

Income Tax	-1.74M
Effective Tax Rate	1.48%

Stock Price Statistics

The stock price has increased by -21.39% in the last 52 weeks. The beta is 0.84, so Enanta Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.84
52-Week Price Change	-21.39%
50-Day Moving Average	7.94
200-Day Moving Average	6.66
Relative Strength Index (RSI)	48.9
Average Volume (20 Days)	186,350

Income Statement

In the last 12 months, Enanta Pharmaceuticals had revenue of 67.64M and earned -116.05M in profits. Earnings per share was -5.48.

Revenue	67.64M
Gross Profit	67.64M
Operating Income	-121.69M
Net Income	-116.05M
EBITDA	-104.51M
EBIT	-106.85M
Earnings Per Share (EPS)	-5.48

Full Income Statement

Balance Sheet

The company has 37.23M in cash and 226.06M in debt, giving a net cash position of -188.82M.

Cash & Cash Equivalents	37.23M
Total Debt	226.06M
Net Cash	-188.82M
Retained Earnings	-323.04M
Total Assets	301.03M
Working Capital	178.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -78.76M and capital expenditures -17.95M, giving a free cash flow of -96.71M.

Operating Cash Flow	-78.76M
Capital Expenditures	-17.95M
Free Cash Flow	-96.71M
FCF Per Share	-4.57

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -179.92% and -171.58%.

Gross Margin	100%
Operating Margin	-179.92%
Pretax Margin	-174.15%
Profit Margin	-171.58%
EBITDA Margin	-154.52%
EBIT Margin	-179.92%
FCF Margin	-142.99%

Dividends & Yields

ENTA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ENTA is $22, which is 178.5% higher than the current price. The consensus rating is "Buy".

Price Target	$22
Price Target Difference	178.5%
Analyst Consensus	Buy
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-1.31
Piotroski F-Score	4